Medlab Clinical Balance Sheet Health

Financial Health criteria checks 4/6

Medlab Clinical has a total shareholder equity of A$7.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$11.3M and A$3.6M respectively.

Key information

Debt to equity ratio

AU$0

Debt

Interest coverage ratio	n/a
Cash	AU$5.54m
Equity	AU$7.75m
Total liabilities	AU$3.58m
Total assets	AU$11.33m

Recent financial health updates

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Oct 05

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Financial Position Analysis

Short Term Liabilities: MDC's short term assets (A$9.2M) exceed its short term liabilities (A$2.5M).

Long Term Liabilities: MDC's short term assets (A$9.2M) exceed its long term liabilities (A$1.1M).

Debt to Equity History and Analysis

Debt Level: MDC is debt free.

Reducing Debt: MDC has no debt compared to 5 years ago when its debt to equity ratio was 9.7%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MDC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MDC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Medlab Clinical Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies